(RTTNews) - Oruka Therapeutics, Inc. (ORKA) on Monday announced positive interim data from its Phase 1 trial of ORKA-002.
The study, conducted in healthy volunteers, evaluated the safety and pharmacokinetics of the drug. Interim results showed a half-life of 75-80 days, supporting the potential for twice-per-year dosing in psoriasis and quarterly dosing in hidradenitis suppurativa. ORKA-002 was well tolerated at all dose levels, with no severe or serious treatment-emergent adverse events reported.
Phase 2 studies for ORKA-002 are expected to begin in the first half of 2026 in psoriasis and the second half of 2026 in hidradenitis suppurativa.
Meanwhile, a Phase 2b study of ORKA-001 dubbed EVERLAST-B is underway with data expected in 2027.
On Friday, Oruka shares closed at $27.86, up 5.53%.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
